Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)

SIMPLE SUMMARY: The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been well-described in the literature. The objective of our retrospective multicenter study was to eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Nardin, Charlée, Hennemann, Aymeric, Diallo, Kadiatou, Funck-Brentano, Elisa, Puzenat, Eve, Heidelberger, Valentine, Jeudy, Géraldine, Samimi, Mahtab, Lesage, Candice, Boussemart, Lise, Peuvrel, Lucie, Rouanet, Jacques, Brunet-Possenti, Florence, Gerard, Emilie, Seris, Alice, Jouary, Thomas, Saint-Jean, Mélanie, Puyraveau, Marc, Saiag, Philippe, Aubin, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377277/
https://www.ncbi.nlm.nih.gov/pubmed/37509227
http://dx.doi.org/10.3390/cancers15143564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377277/
https://www.ncbi.nlm.nih.gov/pubmed/37509227
http://dx.doi.org/10.3390/cancers15143564

Ejemplares similares